BMS Reports Topline P-III (ARISE) Trial Data of Cobenfy as an Adjunctive Therapy for Schizophrenia
Shots:
- The P-III (ARISE) trial assessed Cobenfy (xanomeline & trospium chloride) vs PBO as an adj. therapy to atypical antipsychotics in adults with inadequately controlled schizophrenia symptoms; eligible pts could enter a 52wk. OLE study
- At Wk. 6, trial showed a PANSS score change (1EP) of -14.3 vs -12.2, which was not statistically significant, & changes in 2EPs, incl. PSP (+5.3 vs +5.9) & CGI-S score (-0.6 vs -0.5)
- In post-hoc analysis, the risperidone subgroup showed PANSS score change of -11.3 vs -12.3, while non-risperidone subgroup showed improvement of -15.1 vs -11.7; further analysis is underway, plus discussions with regulators are planned. Full data to be presented at future meetings
Ref: Businesswire | Image: BMS
Related News:- The US FDA Approves BMS’ Opdivo + Yervoy as 1L Treatment for Hepatocellular Carcinoma (HCC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
